CompletedPHASE2, PHASE3NCT00123760

Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer

Studying Thyroid lymphoma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: AHS Cancer Control Alberta
Principal Investigator: Alexander McEwan, MB, MSc, MD, FRCP
AHS Cancer Control Alberta
Intervention: Positron Emission Tomography (PET) scan(procedure)
Enrollment: 10838 target
Eligibility: 15 years · All sexes
Timeline: 2004 – 2008

Study locations (1)

Cross Cancer Institute, Edmonton, Alberta, Canada

Collaborators

Cross Cancer Institute

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00123760 on ClinicalTrials.gov

← Back to all trials